Literature DB >> 14770077

Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update.

Olli Ruuskanen1.   

Abstract

Oral azithromycin suspension has been prescribed to >80 million patients. Children find the color and taste of the oral suspension of azithromycin agreeable, and the drug is well-tolerated. On average 9% of patients have treatment-related adverse events, which are most frequently gastrointestinal complaints. The side effects are mild to moderate and very seldom necessitate withdrawal of the treatment. In addition to the conventional 3-day 10-mg/kg/day regimen and the 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5 regimens, single dose 30 mg/kg and 3-day 20-mg/kg/day regimens are well-tolerated, although these new dosages are associated with more adverse effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14770077     DOI: 10.1097/01.inf.0000112528.75956.41

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Antimalarial activity of tulathromycin in a murine model of malaria.

Authors:  Nicolas Villarino; Joshua E Denny; Nathan W Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

3.  Sensitive and Simplified Detection of Antibiotic Influence on the Dynamic and Versatile Changes of Fecal Short-Chain Fatty Acids.

Authors:  Xiaoya Zhao; Zhenzuo Jiang; Fan Yang; Yan Wang; Xiumei Gao; Yuefei Wang; Xin Chai; Guixiang Pan; Yan Zhu
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 4.  Bronchiectasis in Children: Current Concepts in Immunology and Microbiology.

Authors:  Susan J Pizzutto; Kim M Hare; John W Upham
Journal:  Front Pediatr       Date:  2017-05-29       Impact factor: 3.418

5.  Self-Reported Side Effects following Mass Administration of Azithromycin to Eliminate Trachoma in Amhara, Ethiopia: Results from a Region-Wide Population-Based Survey.

Authors:  Tigist Astale; Eshetu Sata; Mulat Zerihun; Andrew W Nute; Aisha E P Stewart; Melsew Chanyalew; Berhanu Melak; Zebene Ayele; Demelash Gessese; Gedefaw Ayenew; Bizuayehu Gashaw; Zerihun Tadesse; Elizabeth Kelly Callahan; Scott D Nash
Journal:  Am J Trop Med Hyg       Date:  2019-03       Impact factor: 2.345

Review 6.  Antimicrobial therapy in childhood asthma and wheezing.

Authors:  Arne Simon; Oliver Schildgen
Journal:  Treat Respir Med       Date:  2006

7.  Safety of azithromycin in pediatric infectious diseases: a clinical systematic review and meta-analysis.

Authors:  Dongjin Li; Yajun Wang
Journal:  Transl Pediatr       Date:  2021-10

Review 8.  Use and safety of azithromycin in neonates: a systematic review.

Authors:  Coral Smith; Oluwaseun Egunsola; Imti Choonara; Sailesh Kotecha; Evelyne Jacqz-Aigrain; Helen Sammons
Journal:  BMJ Open       Date:  2015-12-09       Impact factor: 2.692

9.  Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants.

Authors:  Rose Marie Viscardi; Michael L Terrin; Laurence S Magder; Natalie L Davis; Susan J Dulkerian; Ken B Waites; Namasivayam Ambalavanan; David A Kaufman; Pamela Donohue; Deborah J Tuttle; Jorn-Hendrik Weitkamp; Hazem E Hassan; Natalie D Eddington
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2020-03-13       Impact factor: 5.747

10.  Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes.

Authors:  Rose M Viscardi; Michael L Terrin; Laurence S Magder; Natalie L Davis; Susan J Dulkerian; Ken B Waites; Marilee Allen; Ajoke Ajayi-Akintade; Namasivayam Ambalavanan; David A Kaufman; Pamela Donohue; Deborah J Tuttle; Jörn-Hendrik Weitkamp
Journal:  Pediatr Res       Date:  2021-03-03       Impact factor: 3.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.